
## Sam Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4185787/publications.pdf Version: 2024-02-01



SAM CHEN

#	Article	IF	CITATIONS
1	The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021, 16, 630-643.	15.6	578
2	Scalable Production of Lipid Nanoparticles Containing Amphotericin B. Langmuir, 2021, 37, 7312-7319.	1.6	7
3	Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. Small, 2021, 17, e2103025.	5.2	29
4	Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach. Langmuir, 2021, 37, 1120-1128.	1.6	50
5	Deep Phenotyping by Mass Cytometry and Single-Cell RNA-Sequencing Reveals LYN-Regulated Signaling Profiles Underlying Monocyte Subset Heterogeneity and Lifespan. Circulation Research, 2020, 126, e61-e79.	2.0	21
6	Lipid nanoparticle technology for therapeutic gene regulation in the liver. Advanced Drug Delivery Reviews, 2020, 159, 344-363.	6.6	187
7	Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Accounts of Chemical Research, 2019, 52, 2435-2444.	7.6	270
8	On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano, 2018, 12, 4787-4795.	7.3	319
9	Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids. Journal of Controlled Release, 2018, 286, 46-54.	4.8	42
10	Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes. Molecular Metabolism, 2017, 6, 1161-1172.	3.0	20
11	Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1377-1387.	1.7	122
12	Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles. Nanoscale, 2017, 9, 13600-13609.	2.8	46
13	A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo. Molecular Therapy - Nucleic Acids, 2016, 5, e348.	2.3	35
14	Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. Journal of Controlled Release, 2016, 235, 236-244.	4.8	204
15	The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA. Molecular Therapy, 2016, 24, 2100-2108.	3.7	38
16	Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems. Journal of Physical Chemistry B, 2015, 119, 8698-8706.	1.2	203
17	Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. Journal of Controlled Release, 2014, 196, 106-112.	4.8	108
18	Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 665-674.	1.7	34

SAM CHEN

#	Article	IF	CITATIONS
19	Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 233-246.	1.7	67
20	Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Molecular Therapy - Nucleic Acids, 2013, 2, e139.	2.3	241
21	Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Molecular Therapy - Nucleic Acids, 2012, 1, e37.	2.3	445